Stability consideration in extemporaneous omeprazole suspension

Chiv Sinly

Program of Aesthetic Sciences and Health, Graduate School, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

Hiroshi Saito

Nihon Pharmaceutical University, Saitama, Japan

Rutchyaporn Anorach

Program of Aesthetic Sciences and Health, Graduate School, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

Naoto Uramaru

Nihon Pharmaceutical University, Saitama, Japan

Teppei Kaku

Nihon Pharmaceutical University, Saitama, Japan

Rachadaporn Benchawattananon

Program in Forensic Science, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand

Chernporn Navanukraw

Program of Aesthetic Sciences and Health, Graduate School, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

Suwannee Panomsuk

Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand

Yoko Kubota

Nihon Pharmaceutical University, Saitama, Japan

Theera Rittirod

Program of Aesthetic Sciences and Health, Graduate School, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

DOI: https://doi.org/10.14456/apst.2023.1

Keywords: Extemporaneous suspension Stability Omeprazole Physicochemical properties

Abstract

meprazole (OMP) is a drug used to treat gastroesophageal reflux disease (GERD). Pharmacists also use commercially available capsules of OMP to prepare extemporaneous suspensions for juvenile and geriatric patients and other patients who are unable to swallow capsules. The stability of extemporaneous preparations should be determined on a regular basis in hospital settings. The aim of this study was to evaluate the effect of temperature on the stability of an OMP extemporaneous suspension. A 2mg/ml OMP extemporaneous suspension was prepared and transferred into plastic bottles for storage at 4±3 °C (refrigerated), 25±5 °C (room temperature) and 45±5 °C (accelerated temperature). After 0, 7, 14, 28, 60, and 90 days, samples were evaluated for appearance and OMP content was determined by high-performance liquid chromatography (HPLC). The percentage deterioration in OMP content was determined for chemical stability. The color of the OMP solutions changed from brownish to dark purple after 7 days at all three storage temperatures. The OMP content of the extemporaneous solutions remained above 90% for 28 days at the refrigerated temperature (90.16±1.70%) and for 7 days at room temperature (92.09±3.44%). There was no OMP detected after day 0 at the accelerated temperature. To conclude, OMP extemporaneous suspensions can be safely stored at 4±3 °C for 28 days. These results will provide hospital pharmacists with stability data to use as a guideline for appropriate storage conditions of OMP extemporaneous preparations.

How to Cite

Sinly, C., Saito, H., Anorach, R., Uramaru, N., Kaku, T., Benchawattananon, R., Navanukraw, C., Panomsuk, S., Kubota, Y., & Rittirod, T. (2023). Stability consideration in extemporaneous omeprazole suspension. Asia-Pacific Journal of Science and Technology, 28(01), APST–28. https://doi.org/10.14456/apst.2023.1

References

Jonkman JHG, Oosterhuis B. Omeprazole: pharmacology, Pharmacokinetics and Interaction. Digestion. 1989;44(Suppl 1):9-17.

Israel DM, Hassall E. Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr. 1998:27(5):568-579.

Shah N, Gossman W. Omeprazole, profiles drug subst. Excipients Relat Methodol. 2021;35:151-262.

European Mediciens Agency. Amsterdam: The Agency; c1995; [Internet]. [cited 2021 Dec 21]. ICH Q3A (R2) Impurities in new drug products. Available from: https://www.ema.europa.eu/en/ich-q3a-r2-impurities-new-drug-substances.

European Mediciens Agency. Amsterdam: The Agency; c1995; [Internet]. [cited 2021 Dec 21]. ICH Q3B (R2) Impurities in new drug products. Available from: https://www.ema.europa.eu/en/ich-q3b-r2-impurities-new-drug-products.

Boscolo O, Perra F, Salvo L, Buontempo F, Lucangioli S. Formulation and stability study of omeprazole oral liquid suspension for pediatric patients. Hosp Pharm. 2019;55(5):314-322.

Gautam PK. Stability of omeprazole oral suspensions compounded in humco flavor sweet sugar free product. Int J Pharm Sci Res. 2017;8(6):111-117.

Jackson R, Lewis P, Brown SD. Comparative stability of compounded omeprazole suspension versus commercial omeprazole kit when stored in oral syringes under refrigerated conditions. J Pharm Technol. 2020;36(5):179.

Baniasadi S, Kobarfard F, Fahimi F. Extemporaneous preparation and stability assessment of omeprazole suspension in a teaching hospital. Int J Pharm Teach. Pract. 2012:13(4):418-421.

Amantea MA, Narang PK. Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography. J Chromatogr. 1988;426(1):216-222.

Riedel A, Leopold CS. Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations. Drug Dev Ind Pharm. 2005;31(2):151-160.

Allen LV. Omeprazole 1 mg/mL or 2 mg/mL oral suspension. US Pharm. 2018;43(12):47-48.

Monzani A, Oderda G. Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review. Clin Exp Gastroenterol. 2010;3(1):17.